MedTrace Logo

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-01-24

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.

Conditions

  • Lupus Arthritis, Systemic Lupus Erythematosus

Interventions

DRUG

AMG 557

AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.

DRUG

Matching Placebo

Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States
  • Australia
  • Denmark
  • France
  • Germany
  • Malaysia
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683695 on ClinicalTrials.gov